MAIA Biotechnology, Inc. ( (MAIA) ) has provided an update.
MAIA Biotechnology has unveiled promising new data from its Phase 2 trial of THIO combined with cemiplimab, showing significant survival benefits for advanced lung cancer patients who have exhausted other treatments. Highlights include median survival follow-ups of over 11 months for third-line treatments. The findings, presented at the SITC Annual Meeting, underscore the potential of THIO in enhancing cancer treatment outcomes. Investors should note these forward-looking statements are subject to uncertainties and risks.
See more insights into MAIA stock on TipRanks’ Stock Analysis page.
